Ethical and Policy Issues in Newborn Screening of Children for Neurologic and Developmental Disorders

被引:10
|
作者
Ross, Lainie Friedman [1 ,2 ,3 ]
机构
[1] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[3] Univ Chicago, Dept Surg, Chicago, IL 60637 USA
关键词
Newborn screening; Genetic screening; Ethics; Public policy; Duchenne muscular dystrophy; Krabbe disease; Fragile X syndrome; FRAGILE-X-SYNDROME; KRABBE DISEASE; MUSCULAR-DYSTROPHY; DUCHENNE; GUIDELINES; GENOME; POPULATION; DECISIONS; ATTITUDES; CARRIERS;
D O I
10.1016/j.pcl.2015.03.009
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Genetic testing for neurologic and developmental disorders spans the spectrum from universal newborn screening for conditions like phenylketonuria to diagnostic testing for suspected genetic conditions, to predictive genetic testing for childhood-onset conditions. Given that virtually all children in the United States undergo genetic screening in the newborn period, this article focuses on 3 actual case studies of neurologic and developmental disorders that have been included or proposed for inclusion in newborn screening programs: Duchenne muscular dystrophy (a neuromuscular disorder), Krabbe disease (a neurodegenerative disorder), and fragile X syndrome (a neurodevelopmental disorder).
引用
收藏
页码:787 / +
页数:13
相关论文
共 50 条